NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
申请人:AurimMed Pharma, Inc.
公开号:US20160137592A1
公开(公告)日:2016-05-19
A series of novel amides showing broad pharmaceutical activity. Compounds described herein are effective as anticonvulsants, chemical countermeasures, and analgesics. Such compounds also show, neuroprotective/neuroreparative effects and activity against spinal muscular atrophy. Such pharmaceutically active compounds show utility in the treatment of central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's, ALS, and Huntington's disease) spasticity, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), and/or traumatic brain and/or spinal cord injuries.
一系列新型酰胺化合物展示了广泛的药理活性。本文所描述的化合物作为抗癫痫药物、化学对抗剂和镇痛剂具有有效性。此类化合物还表现出神经保护/神经修复效应以及对脊髓肌萎缩症的活性。这些具有药理活性的化合物在治疗中枢神经系统(“CNS”)疾病和障碍方面具有实用性,例如焦虑、抑郁、失眠、偏头痛、精神分裂症、神经退行性疾病(如帕金森病、阿尔茨海默病、肌萎缩侧索硬化症和亨廷顿病)、痉挛和躁郁症。此外,这些化合物还可以作为镇痛剂(例如用于慢性或神经性疼痛的治疗)以及作为神经保护剂在中风、创伤性脑和/或脊髓损伤的治疗中有用。